Edwards Lifesciences (NYSE:EW) Issues Quarterly Earnings Results

Edwards Lifesciences (NYSE:EW) issued its earnings results on Tuesday. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04, Zacks reports. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences updated its FY 2025 guidance to 2.400-2.500 EPS and its Q1 2025 guidance to 0.580-0.640 EPS.

Edwards Lifesciences Stock Down 0.2 %

Shares of EW stock traded down $0.15 during trading on Tuesday, hitting $70.95. 3,346,843 shares of the company were exchanged, compared to its average volume of 4,396,275. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $41.85 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 3.64 and a beta of 1.10. The business’s 50-day simple moving average is $72.46 and its 200 day simple moving average is $69.26. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,000 shares of company stock worth $547,430. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Barclays upped their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.19.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.